Please login to the form below

Not currently logged in
Email:
Password:

drug discovery

This page shows the latest drug discovery news and features for those working in and with pharma, biotech and healthcare.

BenevolentAI raises $115m to fund drug development

BenevolentAI raises $115m to fund drug development

BenevolentAI raises $115m to fund drug development. Its technology could cut the early stage drug discovery process by four years, says the company. ... Mulvany thinks the pharma AI has split largely into two groups in recent years, with start-ups that

Latest news

More from news
Approximately 5 fully matching, plus 394 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    Importantly, genetic remedies skip the painstaking middle step of drug discovery. ... For example, the ophthalmic drug Luxturna, approved last year, costs $850, 000 per dose.

  • The ‘Million Hour Challenge’ The ‘Million Hour Challenge’

    Over 500, 000 hours saved by reducing the administrative burden for scientists in drug discovery and development and standardising and digitising clinical trial operations.

  • The tipping point The tipping point

    The first is the rate of drug discovery and innovation in general, and the associated budget impact which continues to grow exponentially. ... Put simply, biosimilars enable innovation at a time when the mismatch between the rate of drug discovery and

  • Is AI changing the future of healthcare? Is AI changing the future of healthcare?

    Big pharma is investing in AI; there are now dedicated AI-based drug discovery firms that big players such as GSK, Merck, Sanofi and J&J are turning to, with significant ... In drug development AI is being used to reduce the time and cost associated with

  • European venture funding for the life science sector European venture funding for the life science sector

    This broad category covering everything from clinical grade wearables, smart diagnostics to AI-enabled chat-bots and drug discovery companies, is attracting investment from technology as well as healthcare investors.

More from intelligence
Approximately 0 fully matching, plus 47 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Metrion Biosciences, the specialist ion channel contract research and drug discovery group, has appointed Dr Barry Kenny and Dr Andrew Southan to its board of directors, a move that will see ... Dr Kenny is currently chief business officer of Heptares

  • Concept Life Sciences adds to its scientific and commercial team Concept Life Sciences adds to its scientific and commercial team

    Also joining the company is Dr Tim Calvert (pictured left), who becomes its vice president of business development, integrated discovery services, Europe. ... Dr Calvert has experience in the delivery of integrated drug discovery and development solutions

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    Contract research organisation and drug discovery business Metrion Biosciences has established a scientific advisory board, which will provide strategic scientific guidance to the company. ... Dr Tom Colatsky also joins the board following over 30 years

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    Storm Therapeutics, a company focused on the discovery of small molecule therapies has appointed Professor Thomas Cech as its scientific advisor. ... As a leader in the field of RNA biology, Tom’s in-depth knowledge, insight and experience will be

  • Robert Freisen joins Ablynx Robert Freisen joins Ablynx

    Dr Edwin Moses, chief executive officer of Ablynx, said: “Robert brings an extensive track record of successfully initiating and executing new drug discovery programmes as well as building strong research organisations.

More from appointments
Approximately 0 fully matching, plus 67 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics